Quest Diagnostics Incorporated (DGX:NYSE) closed at $241.89 on October 23, 2026, down 0.57% on the day. The stock trades 2.8% below its 52-week high of $248.84 and 41.3% above its 52-week low of $171.18. Over the past year, it gained 32.8%. Quest Diagnostics Incorporated is part of the Health Care sector (Medical Specialities).
In 252 trading sessions since October 23, 2025, DGX closed higher on 119 days (47%). Its best day was July 23, 2026 (+8.61%) and its worst was September 22, 2026 (-4.13%). It never moved 10% or more in a single session. It opened at least 5% above the previous day's high 1 time.
Quest Diagnostics Incorporated provides diagnostic testing information and services in the United States and internationally. The company's Diagnostic Information Services business segment develops and delivers diagnostic testing information and services, such as routine testing, gene-based and esoteric testing, and drugs-of-abuse testing, as well as anatomic pathology services, and related services and insights. This segment offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, Focus Diagnostics, Athena Diagnostics, ExamOne, Quanum, and Care360 brands to patients, clinicians, hospitals, integrated delivery networks, health plans, employers, and accountable care organizations through a network of laboratories, patient service centers, and phlebotomists in physician offices. Its Diagnostic Solutions segment offers risk assessment services for the life insurance industry; and health information technology solutions for healthcare organizations and clinicians. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Madison, New Jersey.
Find more stocks like DGX with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.